查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1847843

植入周圍炎市場（按產品類型、治療方法、最終用戶、分銷管道、植入材料和嚴重程度）—2025-2032 年全球預測

Peri-implantitis Market by Product Type, Treatment Modality, End User, Distribution Channel, Implant Material, Severity - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，植入周圍炎市場將成長 22.7 億美元，複合年成長率為 10.13%。

主要市場統計數據
基準年2024年 10.5億美元
預計2025年 11.5億美元
預測年份：2032年 22.7億美元
複合年成長率（%） 10.13%

植體周圍植入是連結臨床實踐、材料科學和醫療保健系統的挑戰，需要多學科解決方案。

隨著植入長期存活率和患者期望的趨同，植體周圍植入已成為臨床醫生、器材製造商和醫療保健系統的焦點。本介紹認為植入周圍炎不僅僅是一種臨床併發症，而是一項涉及生醫材料、臨床通訊協定、監管審查和以患者為中心的治療結果等多方面的挑戰。植入使用率的上升、對美觀和功能壽命的重視以及日益成長的監管關注，正在推動對能夠兼顧預防和有效干預的綜合解決方案的需求。

臨床醫生正在應對日益增多的治療套件，從保守的非手術治療到複雜的再生手術，而製造商則透過輔助器具、新型膜、植入材料和輔助藥物來應對。同時，支付方和醫療系統正在仔細審查各種治療方案的價值和長期成本影響，這推動了對特定干涉措施與持續臨床效益之間關聯證據的需求。本引言概述了當前產業活動和近期策略重點所依賴的臨床獎勵、相關人員激勵措施和創新促進因素，為更深入的分析奠定了基礎。

生物材料、診斷和多學科通訊協定的進步如何重塑植體周圍植入治療的臨床路徑和產品開發

生醫材料、微創技術、數位化診斷以及更嚴謹的實證依證（強調長期組織穩定性）的進步，正在推動植體植入炎治療的變革性轉變。移植物成分和膜吸收特性的創新使臨床醫生能夠更精確地根據患者的生物學特徵制定再生策略，而雷射輔助治療方法和改進的輔助設備正在拓展非手術治療方案，從而延緩或減少侵入性干預的需求。伴隨這一轉變的是，更廣泛地轉向優先保留軟組織結構並促進骨再生的治療方案。

同時，更精準的椅旁評估，包括軟組織發炎、植入探查和影像學檢查，正在提高診斷準確性，並促成更早、更有針對性的治療。整合牙周病醫師、修復牙醫和外科醫生的多學科護理的興起，正在提高協調管理的標準，並為整合產品和服務的提供創造機會。此外，監管部門對臨床證據和上市後監測的重視，正促使製造商投資穩健的療效研究，從而將產品開發的重點轉向展示長期性能和安全性。

關稅導致的供應鏈中斷和採購重組對臨床連續性、籌資策略和商業性彈性的影響

政策變化可能導致關稅變化，這促使相關人員更加關注跨境供應鏈的韌性和籌資策略。對牙科材料、植入輔助器具或進口手術器械徵收關稅可能會增加到岸成本，對供應商多元化構成壓力，並加速本地生產或近岸外包進程。事實上，採購團隊和製造商正在評估其採購足跡以減輕影響，優先考慮多方採購，並重新審查合約條款，以保持利潤率並保障臨床醫生的物資供應。

關稅不僅會影響單位成本，還會影響庫存策略和營運成本管理。醫療系統和大型牙科集團可能會採取以下應對措施：增加關鍵耗材的緩衝庫存、重新協商分銷契約，或轉向契約製造外包，以實現植入物、膜和一次性輔助器具的本地化生產。隨著企業尋求更具韌性和靈活性的市場管道，這些舉措也提升了經銷商關係和線上管道的策略價值。最終，關稅主導的壓力強化了供應鏈透明度、服務成本分析和情境規劃的重要性，以維持臨床連續性和競爭優勢。

將產品設計、臨床通訊協定和分銷策略與最有可能實現採用和臨床影響的領域聯繫起來的細分洞察

細分分析提供了一個細緻的視角，闡明了臨床需求和機會在植體植入炎治療過程中的交會點。按產品類型分類，該市場包括輔助器械、雷射治療、藥物治療和手術治療。在手術方法方面，移植物類型和膜的選擇代表了不同的臨床和監管途徑，移植物材料分為同種異體移植物、自體移植物、合成移植物和異質骨移植，膜則根據性能特徵（例如不可吸收或可吸收）進行區分。這種細緻的分類表明，外科創新的重點是將特定的移植物材料與旨在可預測分解和維持間隙的膜相結合的組合解決方案。

縱觀治療方式，我們可以看出非手術策略（例如局部抗生素治療和機械清創）與手術方案（包括再生手術和消融治療）之間的差異。這些治療方法之間的平衡取決於疾病嚴重程度和臨床醫生的偏好，非手術方案在早期管理中發揮更大的作用，而再生方法則在需要保存或修復組織時佔據中心地位。終端使用者細分涵蓋了門診手術中心、牙科診所和醫院獨特的採購和臨床工作流程，每個流程都考慮了不同的採購週期、報銷互動和手術量。分銷管道（例如直銷、分銷商網路、線上通路）會改變商業性准入和支援模式，而鈦和氧化鋯之間的植入材料選擇以及臨床嚴重程度等級（輕度、中度和重度）則進一步完善了產品定位和臨床通訊協定選擇。整合這些細分維度，可以讓我們策略性地了解哪些有針對性的臨床證據、教育和上市合作能夠最有效地加速應用。

法律規範、臨床採用模式和供應鏈結構的區域差異影響了植入炎的治療和商業化途徑

區域動態對於理解臨床實踐、法律規範和供應鏈結構如何影響植入炎的管理至關重要。在美洲，高病例量、牙科服務機構的整合以及對循證報銷的關注，正在影響先進再生材料和輔助器具的採用曲線。該地區私人診所和報銷診所的混合模式，鼓勵價值驗證和長期結果數據來支持昂貴的臨床干預措施。

歐洲、中東和非洲的監管環境和公共衛生結構差異很大，導致新材料和新技術的採用時間也各不相同。在某些市場，集中採購和醫院主導的項目支持標準化產品系列，而私人專科診所則推動創新雷射和生技藥品的早期採用。亞太地區的特點是臨床現代化進程迅速，國內製造能力不斷提高，牙科教育和專科培訓投入不斷增加，這些因素共同加速了植入材料和輔助技術的程序採用和本地創新。這些地區差異凸顯了量身定做的監管策略、本地臨床證據生成以及反映付款人結構和提供者生態系統的分銷模式的重要性。

競爭格局的特點是基於證據的產品差異化、策略夥伴關係以及影響臨床採用和規模的分銷選擇

植體植入炎治療的競爭態勢由產品創新、臨床證據產生、策略夥伴關係關係以及以服務為導向的商業模式共同決定。主要企業憑藉專有的移植配方、具有可預測吸收特性的膜技術以及可整合到現有臨床工作流程的輔助設備，脫穎而出。成功越來越依賴在真實臨床環境中展示可重複結果的能力、為臨床醫生提供高品質的培訓和基於案例的教育支持，以及維持強力的上市後監測以促進產品的迭代改進。

器材製造商、研究機構和專科診所之間的策略聯盟正在加速臨床檢驗，並建立值得信賴的臨床倡導者。同時，能夠有效應對監管流程並擴大複雜生物材料生產的公司正在獲得營運優勢。銷售策略各不相同，有些公司優先發展面對面的客戶關係，而有些公司則利用經銷商網路和線上管道來擴大覆蓋範圍。那些將產品系列與報銷途徑相結合，並投資於數位工具以促進臨床醫生參與和患者溝通的公司，更有能力將臨床前景轉化為持續的應用。

可行的策略重點在於證據生成、供應彈性以及加速臨床應用和競爭差異化的獨特商業模式

產業領導者應優先考慮臨床證據產生、供應鏈韌性和有針對性的商業策略，以加速永續成長。強調方案標準化和結果衡量的臨床醫生教育計畫將有助於在現實世界中推廣應用。從供應鏈的角度來看，多元化製造地和製定緊急庫存計劃可以減輕國際貿易變化和關稅造成的成本波動的影響。

複雜的生技藥品和勞動密集型再生系統受益於直銷和專業的臨床醫生支持，而輔助設備和耗材則可以透過經銷商和線上管道實現規模化。與學術中心和專業網路建立策略聯盟可以提升臨床可信度，而整合有助於病例記錄和患者追蹤的數位化工具，則可以在競爭激烈的市場中實現產品差異化。最後，設計產品系列既能適應鈦和氧化鋯植入生態系統，又能涵蓋從輕度到重度各種疾病嚴重程度的產品組合，可以擴大臨床應用範圍並降低應用門檻。

採用嚴格的多源研究方法，結合臨床文獻綜述、專家訪談和跨細分分析來支持策略結論

本分析背後的調查方法結合了同行評審臨床文獻、監管申報資料、技術產品文件的系統性綜述，以及對執業臨床醫生、採購主管和行業高管的訪談，從而提供關於技術趨勢、臨床通訊協定和商業性動態的全面視角。資料收集著重於臨床結果、器械附加檔和監管摘要的一級資訊來源，並輔以描述最終用戶實踐模式和採購考慮的定性訪談。

分析方法包括：跨細分市場映射，用於識別產品創新與臨床需求的交集；基於情境的供應鏈壓力測試，用於探索關稅和採購的影響；以及分銷模式與最終用戶購買行為的比較評估。在整個過程中，我們整合了來自多個資訊來源和觀點的見解，以確保研究的穩健性，並突出需要進一步研究或在局部檢驗的不確定性。

整合臨床需求、創新途徑和業務需求，制定推動植入炎治療的策略議程

植體周圍植入對整個牙科生態系統的相關人員來說，既是臨床挑戰，也是策略機會。生物材料、精準診斷和微創治療方法的進步正在擴展臨床醫生可用的套件，而分銷和供應鏈動態也在應對政策和商業性壓力而不斷發展。隨著護理途徑轉向循證、注重患者保存的策略，那些將產品創新與可靠的療效數據和靈活的商業模式相結合的製造商和供應商將獲得巨大的價值。

持續的進展取決於多學科合作、對真實世界證據產生的投入以及能夠降低關稅波動等外部風險的務實供應鏈規劃。尋求改善患者預後的臨床醫生應強調早期發現和規範的干涉措施，而支付方和衛生系統則應獎勵那些能夠持續臨床效益的治療。本結論強調了整合臨床卓越性、營運韌性和策略性商業化的通用必要性，將植入周圍炎治療從一次性治療轉變為可預測的長期植入保存。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 越來越多採用雷射輔助手術通訊協定治療植體周圍植入
  • 增強數位成像​​和人工智慧診斷的整合，用於早期植入炎檢測
  • 開發抗菌肽塗層植入表面以防止生物膜形成
  • 使用生長因子和幹細胞的個人化再生療法的需求不斷增加
  • 照護現場微生物組檢測的出現有助於客製化治療策略

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章植入周圍炎市場（依產品類型）

  • 輔助設備
  • 雷射治療
  • 藥物治療
  • 手術治療
    • 移植類型
      • 同種異體移植
      • 自體移植
      • 合成
      • 異種移植
    • 膜類型
      • 不可吸收
      • 吸收性

第9章植入周圍炎市場（依治療方法）

  • 非手術
    • 局部抗生素治療
    • 機械清創
  • 外科手術
    • 再生醫學
    • 切除手術

第 10 章植入周圍炎市場（依最終用戶分類）

  • 門診手術中心
  • 牙醫診所
  • 醫院

第 11 章植入周圍炎市場（依分銷管道）

  • 直銷
  • 經銷商
  • 線上管道

第 12 章植入周圍炎市場（依植入材質）

  • 鈦
  • 氧化鋯

第 13 章植入周圍炎市場（依嚴重程度）

  • 溫和的
  • 緩和
  • 嚴重

第 14 章植入周圍炎市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 15 章植入市場：依類別

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章植入周圍炎市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Institut Straumann AG
    • DENTSPLY SIRONA Inc.
    • Zimmer Biomet Holdings, Inc.
    • Nobel Biocare Services AG
    • Osstem Implant Co., Ltd.
    • MIS Implants Technologies Ltd.
    • Geistlich Pharma AG
    • BioHorizons IPH, Inc.
    • CAMLOG Biotechnologies GmbH
    • Osteogenics Biomedical, Inc.
Product Code: MRR-4103B31E019B

The Peri-implantitis Market is projected to grow by USD 2.27 billion at a CAGR of 10.13% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.05 billion
Estimated Year [2025] USD 1.15 billion
Forecast Year [2032] USD 2.27 billion
CAGR (%) 10.13%

An integrative framing of peri-implantitis as a converging clinical, material science, and health systems challenge demanding multidisciplinary solutions

Peri-implantitis has emerged as a focal point for clinicians, device manufacturers, and health systems as long-term implant survival and patient expectations converge. This introduction frames peri-implantitis not merely as a clinical complication but as a multifaceted challenge that spans biomaterials, clinical protocols, regulatory scrutiny, and patient-centered outcomes. Rising implant utilization, greater emphasis on esthetic and functional longevity, and heightened regulatory attention have collectively intensified the need for integrated solutions that address both prevention and effective intervention.

Clinicians are navigating an expanding therapeutic toolkit that ranges from conservative, non-surgical regimens to complex regenerative surgeries, and manufacturers are responding with adjunctive devices, novel membranes, graft materials, and pharmacologic adjuncts. At the same time, payers and health systems are scrutinizing procedural value and long-term cost implications, driving demand for evidence that links specific interventions to durable clinical benefits. This introduction sets the stage for deeper analysis by outlining the clinical imperatives, stakeholder incentives, and innovation drivers that underpin current industry activity and near-term strategic priorities.

How advances in biomaterials, diagnostics, and interdisciplinary protocols are reshaping clinical pathways and product development across peri-implantitis care

Transformative shifts in peri-implantitis care are being driven by converging advances in biomaterials, minimally invasive techniques, digital diagnostics, and a more rigorous evidence base that emphasizes long-term tissue stability. Innovations in graft composition and membrane resorption profiles are enabling clinicians to tailor regenerative strategies more precisely to patient biology, while laser-assisted modalities and improved adjunctive devices are expanding non-surgical options that can delay or reduce the need for invasive intervention. These shifts are accompanying a broader move toward protocols that prioritize preservation of soft tissue architecture alongside osseous regeneration.

Simultaneously, diagnostic sophistication is improving, with more accurate chairside assessments of soft tissue inflammation, peri-implant probing profiles, and imaging modalities that support earlier, more targeted treatment. The growth of interdisciplinary care pathways-integrating periodontists, restorative dentists, and surgical specialists-has elevated the standard for coordinated management and created opportunities for integrated product-service offerings. Regulatory emphasis on clinical evidence and post-market surveillance is also prompting manufacturers to invest in robust outcomes research, which in turn is reshaping product development priorities toward demonstrable long-term performance and safety.

Implications of tariff-driven supply chain disruption and procurement realignment for clinical continuity, sourcing strategies, and commercial resilience

The prospect of tariff changes originating from policy shifts has sharpened stakeholder attention to cross-border supply chain resilience and procurement strategies. Tariffs applied to dental materials, implant adjuncts, or imported surgical instruments can increase landed costs, compel supplier diversification, and accelerate local manufacturing or nearshoring initiatives. In practice, procurement teams and manufacturers are evaluating sourcing footprints to mitigate exposure, prioritizing multi-sourcing, and re-examining contract terms to preserve margin and maintain product availability for clinicians.

Beyond unit cost implications, tariffs influence inventory strategies and working capital management. Health systems and larger dental groups may respond by increasing buffer stocks of critical consumables, renegotiating distribution agreements, or shifting to contract manufacturing arrangements that localize production of grafts, membranes, or disposable adjunctive devices. The dynamic also elevates the strategic value of distributor relationships and online channels as firms seek resilient and flexible pathways to market. Ultimately, tariff-driven pressures reinforce the importance of supply chain transparency, cost-to-serve analyses, and scenario planning to sustain clinical continuity and preserve competitive positioning.

Segment-level insights that connect product design, clinical protocols, and distribution strategies to where adoption and clinical impact are most likely to converge

Segmentation analysis provides a nuanced lens that clarifies where clinical demand and commercial opportunity intersect across the peri-implantitis care continuum. When examined through product type, the market encompasses adjunctive devices, laser treatment, pharmacological treatment, and surgical treatment; within surgical approaches, graft types and membrane options present distinct clinical and regulatory pathways, with graft materials categorized as allograft, autograft, synthetic, and xenograft, and membranes differentiated by non-resorbable versus resorbable performance characteristics. This granularity reveals that surgical innovation is often concentrated in combination solutions that link specific graft materials to membranes engineered for predictable degradation and space maintenance.

Viewing the landscape by treatment modality highlights a split between non-surgical strategies-such as local antibiotic therapy and mechanical debridement-and surgical protocols that include regenerative procedures and resective measures. The balance between these modalities is shaped by disease severity and clinician preference, with non-surgical options playing a larger role in early-stage management and regenerative approaches becoming central when tissue preservation and restoration are required. End-user segmentation captures divergent procurement and clinical workflows across ambulatory surgery centers, dental clinics, and hospitals, each presenting distinct purchasing cycles, reimbursement interactions, and procedural throughput considerations. Distribution channels-whether direct sales, distributor networks, or online channels-modulate commercial access and support models, while implant material choice between titanium and zirconia and clinical severity strata of mild, moderate, and severe cases further refine product positioning and clinical protocol selection. Integrating these segmentation dimensions enables a strategic view of where targeted clinical evidence, education, and go-to-market alignment can most effectively accelerate adoption.

Regional contrasts in regulatory frameworks, clinical adoption patterns, and supply chain structures that shape peri-implantitis care and commercialization pathways

Regional dynamics are critical to understanding how clinical practices, regulatory frameworks, and supply chain architectures shape peri-implantitis management. In the Americas, procedural volumes, consolidated dental service organizations, and a strong emphasis on evidence-based reimbursement mechanisms influence adoption curves for advanced regenerative materials and adjunctive devices. This region's mix of private-pay and insurance-driven care incentivizes value demonstrations and long-term outcome data to support premium clinical interventions.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory regimes and public health structures vary significantly, resulting in diverse adoption timelines for new materials and techniques. In some markets, centralized procurement and hospital-led programs favor standardized product portfolios, whereas private specialty clinics drive early adoption of innovative lasers and biologics. The Asia-Pacific region is characterized by rapid clinical modernization, growing domestic manufacturing capabilities, and increasing investment in dental education and specialist training, which together accelerate both procedural uptake and local innovation in implant materials and adjunctive technologies. These regional contrasts underscore the importance of tailored regulatory strategies, localized clinical evidence generation, and distribution models that reflect payer structures and provider ecosystems.

Competitive landscape characterized by evidence-driven product differentiation, strategic partnerships, and distribution choices that influence clinical adoption and scale

Competitive dynamics in peri-implantitis care are defined by a combination of product innovation, clinical evidence generation, strategic partnerships, and service-oriented commercial models. Leading companies are differentiating through proprietary graft formulations, membrane technologies with predictable resorption profiles, and adjunctive devices that integrate into established clinical workflows. Success is increasingly tied to the ability to demonstrate reproducible outcomes in real-world settings, to support clinicians with high-quality training and case-based education, and to maintain robust post-market surveillance that informs iterative product improvements.

Strategic alliances between device manufacturers, research institutions, and specialty clinics are accelerating clinical validation and building trusted clinical advocates. Meanwhile, firms that can efficiently navigate regulatory pathways and scale manufacturing for complex biological materials gain an operational edge. Distribution strategies vary, with some companies favoring direct engagement for high-touch accounts while others leverage distributor networks and online channels to broaden reach. Companies that align product portfolios with reimbursement pathways and that invest in digital tools to facilitate clinician engagement and patient communication are better positioned to convert clinical promise into sustained utilization.

Actionable strategic priorities focused on evidence generation, supply resilience, and tailored commercial models to accelerate clinical adoption and competitive differentiation

Industry leaders should prioritize a combination of clinical evidence generation, supply chain resilience, and targeted commercial strategies to accelerate sustainable growth. Investing in prospective clinical studies and pragmatic registries will strengthen value propositions and support payer discussions, while clinician education programs that emphasize protocol standardization and outcomes measurement will enhance real-world adoption. From a supply chain perspective, diversifying manufacturing footprints and establishing contingency inventory plans can reduce exposure to international trade shifts and tariff-driven cost variability.

Commercially, aligning distribution strategies with the end-user profile is essential: complex biologics and high-touch regenerative systems benefit from direct sales and dedicated clinician support, whereas adjunctive devices and consumables can leverage distributors and online channels for scale. Strategic collaborations with academic centers and specialty networks can amplify clinical credibility, and embedding digital tools that facilitate case documentation and patient follow-up will differentiate offerings in a crowded market. Finally, designing product portfolios that accommodate both titanium and zirconia implant ecosystems and that address the full spectrum of disease severity-from mild to severe-will broaden clinical applicability and reduce barriers to adoption.

A rigorous multi-source research approach blending clinical literature review, expert interviews, and cross-segmentation analysis to underpin strategic conclusions

The research methodology underpinning this analysis combined a systematic review of peer-reviewed clinical literature, regulatory filings, technical product documentation, and interviews with practicing clinicians, procurement leaders, and industry executives to create an integrated view of technological trends, clinical protocols, and commercial dynamics. Data collection emphasized primary-source clinical outcomes, device labeling, and regulatory summaries, supplemented by qualitative interviews that contextualized practice patterns and procurement considerations across end users.

Analytical methods included cross-segmentation mapping to identify where product innovation intersects with clinical need, scenario-based supply chain stress-testing to examine tariff and sourcing implications, and comparative evaluation of distribution models relative to end-user purchasing behavior. Throughout, care was taken to triangulate findings across multiple sources and expert perspectives to ensure robustness and to highlight prevailing uncertainties that warrant further investigation or localized validation.

Synthesis of clinical imperatives, innovation pathways, and operational imperatives that together define the strategic agenda for advancing peri-implantitis care

Peri-implantitis presents both a clinical challenge and a strategic opportunity for stakeholders across the dental ecosystem. Advances in biomaterials, diagnostic precision, and minimally invasive modalities are expanding the toolkit available to clinicians, while distribution and supply chain dynamics are evolving in response to policy and commercial pressures. As care pathways shift toward evidence-driven, preservation-focused strategies, manufacturers and providers that align product innovation with robust outcome data and resilient commercial models will capture disproportionate value.

Sustained progress will depend on interdisciplinary collaboration, investment in real-world evidence generation, and pragmatic supply chain planning that mitigates external risks such as tariff fluctuations. Clinicians seeking to improve patient outcomes should emphasize early detection and protocolized intervention, while payers and health systems should incentivize treatments that demonstrate durable clinical benefit. The conclusion underscores a shared imperative: integrating clinical excellence, operational resilience, and strategic commercialization to transform peri-implantitis care from episodic treatment toward predictable, long-term implant preservation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of laser-assisted surgery protocols in peri-implantitis management
  • 5.2. Increasing integration of digital imaging and AI diagnostics for early peri-implantitis detection
  • 5.3. Development of antimicrobial peptide-coated implant surfaces to prevent biofilm formation
  • 5.4. Growing demand for personalized regenerative therapies using growth factors and stem cells
  • 5.5. Emergence of point-of-care microbiome testing to tailor peri-implantitis treatment strategies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Peri-implantitis Market, by Product Type

  • 8.1. Adjunctive Devices
  • 8.2. Laser Treatment
  • 8.3. Pharmacological Treatment
  • 8.4. Surgical Treatment
    • 8.4.1. Graft Type
      • 8.4.1.1. Allograft
      • 8.4.1.2. Autograft
      • 8.4.1.3. Synthetic
      • 8.4.1.4. Xenograft
    • 8.4.2. Membrane Type
      • 8.4.2.1. Non-Resorbable
      • 8.4.2.2. Resorbable

9. Peri-implantitis Market, by Treatment Modality

  • 9.1. Non Surgical
    • 9.1.1. Local Antibiotic Therapy
    • 9.1.2. Mechanical Debridement
  • 9.2. Surgical
    • 9.2.1. Regenerative Procedures
    • 9.2.2. Resective Procedures

10. Peri-implantitis Market, by End User

  • 10.1. Ambulatory Surgery Centers
  • 10.2. Dental Clinics
  • 10.3. Hospitals

11. Peri-implantitis Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Distributors
  • 11.3. Online Channels

12. Peri-implantitis Market, by Implant Material

  • 12.1. Titanium
  • 12.2. Zirconia

13. Peri-implantitis Market, by Severity

  • 13.1. Mild
  • 13.2. Moderate
  • 13.3. Severe

14. Peri-implantitis Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Peri-implantitis Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Peri-implantitis Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Institut Straumann AG
    • 17.3.2. DENTSPLY SIRONA Inc.
    • 17.3.3. Zimmer Biomet Holdings, Inc.
    • 17.3.4. Nobel Biocare Services AG
    • 17.3.5. Osstem Implant Co., Ltd.
    • 17.3.6. MIS Implants Technologies Ltd.
    • 17.3.7. Geistlich Pharma AG
    • 17.3.8. BioHorizons IPH, Inc.
    • 17.3.9. CAMLOG Biotechnologies GmbH
    • 17.3.10. Osteogenics Biomedical, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PERI-IMPLANTITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. PERI-IMPLANTITIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. PERI-IMPLANTITIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PERI-IMPLANTITIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PERI-IMPLANTITIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PERI-IMPLANTITIS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ADJUNCTIVE DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ADJUNCTIVE DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ADJUNCTIVE DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ADJUNCTIVE DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ADJUNCTIVE DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ADJUNCTIVE DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LASER TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LASER TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LASER TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LASER TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LASER TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LASER TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ALLOGRAFT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ALLOGRAFT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ALLOGRAFT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ALLOGRAFT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ALLOGRAFT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ALLOGRAFT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AUTOGRAFT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AUTOGRAFT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AUTOGRAFT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AUTOGRAFT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AUTOGRAFT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AUTOGRAFT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SYNTHETIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SYNTHETIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SYNTHETIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY XENOGRAFT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY XENOGRAFT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY XENOGRAFT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY XENOGRAFT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY XENOGRAFT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY XENOGRAFT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON-RESORBABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON-RESORBABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON-RESORBABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON-RESORBABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON-RESORBABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON-RESORBABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESORBABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESORBABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESORBABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESORBABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESORBABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESORBABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LOCAL ANTIBIOTIC THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LOCAL ANTIBIOTIC THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LOCAL ANTIBIOTIC THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LOCAL ANTIBIOTIC THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LOCAL ANTIBIOTIC THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LOCAL ANTIBIOTIC THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MECHANICAL DEBRIDEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MECHANICAL DEBRIDEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MECHANICAL DEBRIDEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MECHANICAL DEBRIDEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MECHANICAL DEBRIDEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MECHANICAL DEBRIDEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY REGENERATIVE PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY REGENERATIVE PROCEDURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY REGENERATIVE PROCEDURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY REGENERATIVE PROCEDURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY REGENERATIVE PROCEDURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY REGENERATIVE PROCEDURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESECTIVE PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESECTIVE PROCEDURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESECTIVE PROCEDURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESECTIVE PROCEDURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESECTIVE PROCEDURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESECTIVE PROCEDURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DENTAL CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DENTAL CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DENTAL CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DENTAL CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DENTAL CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DENTAL CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY TITANIUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY TITANIUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY TITANIUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY TITANIUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY TITANIUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY TITANIUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ZIRCONIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ZIRCONIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ZIRCONIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ZIRCONIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ZIRCONIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ZIRCONIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MILD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MILD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MILD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MILD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MILD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MILD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MODERATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MODERATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MODERATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MODERATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MODERATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SEVERE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SEVERE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SEVERE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SEVERE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SEVERE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 323. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 324. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 325. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 326. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 327. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 328. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 329. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2025-2032 (USD MILLION)
  • TABLE 331. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2024 (USD MILLION)
  • TABLE 332. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2025-2032 (USD MILLION)
  • TABLE 333. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 334. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 335. MIDD